公开(公告)号：US20220288069A1

公开(公告)日：2022-09-15

申请号：US17626486

申请日：2020-07-17

申请人： BridGene Biosciences, Inc.

发明人： Chao Zhang ,  Ping Cao ,  Michael J. Bishop

IPC分类号： A61K31/506 ,  C07D403/12 ,  C07D413/14 ,  C07D403/14 ,  C07D417/12 ,  C07D417/14 ,  C07D403/06 ,  C07D209/34 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/404

摘要： The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kinase inhibitor compounds.

公开(公告)号：US20220276253A1

公开(公告)日：2022-09-01

申请号：US17630815

申请日：2020-08-04

申请人： BridGene Biosciences, Inc.

发明人： Ping Cao ,  Yuan Yuan ,  Chao Zhang

IPC分类号： G01N33/58 ,  G01N33/68

摘要： The present disclosure provides a profiling method based on comparative mass spectrometry analysis for identifying and quantifying the covalent interactions of electrophilic compounds with diverse proteins in complex proteomes, as well as compositions for performing the method.

公开(公告)号：US20220218703A1

公开(公告)日：2022-07-14

申请号：US17430621

申请日：2020-02-14

申请人： BridGene Biosciences, Inc.

发明人： Ping Cao ,  Chao Zhang ,  Michael J. Bishop

IPC分类号： A61K31/506 ,  A61K45/06 ,  C07D405/14 ,  C07D401/04 ,  C07D401/14

摘要： The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.